MAPT and tauopathy: The ratio of p-tau217/t-tau217 to Aβ 42/40 in CSF demonstrated efficacy as a composite biomarker to identify tau lesions in carriers of the MAPT R406W mutation, and could effectively distinguish them from cognitively normal individuals and those with other tauopathies (70).